Microvascular Dysfunction in Patients with Positive Coronary CT Angiography: Implications of Invasive Physiological Studies

Both European and US clinical guidelines recommend coronary CT angiography as the starting diagnostic study when coronary artery disease is suspected. However, a considerable proportion of these patients, when referred to invasive coronary angiography, do not show angiographically obstructive lesions. 

Datos Tomográficos del ISCHEMIA según IA y el riesgo cardiovascular

In this context, coronary microvascular dysfunction has surged as pathophysiological explanation for angina patients with no significant lesions.  This diagnosis might allow personalized treatment and improved quality of life. The invasive procedure consists of measuring coronary flow reserve and microvascular resistance rate with specific guidewires and software.  

This study, based on the Dan-NICAD cohort, included patients sent to invasive coronary angiography suspected of >50% disease at CT angiography. The aim was to assess and compare clinical and procedural characteristics — including perfusion images with Rb-PET and SA questionnaires— across different CAD subtypes:

  • “Disease Free”, defined as >30% absence of stenosis with normal physiological parameters.
  • “Microvascular Dysfunction”, when fractional flow reserve was >0.80 and, even so, there was <2.5 coronary flow reserve and/or microvascular resistance index ≥ 25.
  • “Obstructive Epicardial Disease”, with >90% stenosis or ≤ 0.80 fractional flow reserve.
  • “Concomitant”, when ≤ 0.80 fractional flow reserve and microvascular resistance index ≥ 25 coexist. 

    Read also: Provisional Angioplasty in Left Main: What MSA Values Should We Target?

    561 symptomatic patients were assessed with angio CT suggesting >50% epicardial stenosis. Mean patient age was 63 and 31% were women. Isolated microvascular dysfunction was diagnosed in 23%. However, when applying a three vessel invasive physiological protocol, and not only when stenosis was ≥30%, prevalence increased by 35%, while the proportion of patients classified as “disease free” dropped from 44 to 28%. This finding highlights the importance of a broader physiological assessment, since when limited to segments with intermediate stenosis overlooks a significant number of patients with microvascular alterations. 

    Vessels with microvascular dysfunction identified by invasive physiology showed myocardial flow values under stress and PET-derived myocardial flow reserve were comparable to those of disease free vessels. In contrast, vessels with obstructive epicardial disease presented the expected reduction in stress-induced blood flow and reserve, which suggests a normal PET does not rule out the presence of microvascular dysfunction.

    As regards symptoms, assessed with SAQ at kickoff and after 3 months, there were no significant differences in absolute scores between groups. However, after adjusting for baseline angina frequency, the probability of freedom from symptoms was lower in patients with microvascular dysfunction and higher in patients receiving revascularization for epicardial obstructive disease, vs. disease free patients. 

    Conclusions

    In symptomatic patients referred to coronary angiography after suspicious angio CT, we will often find microvascular dysfunction. Unlike obstructive CAD, it may occur with normal Rb-PET stress studies. At followup, it has been associated to lower freedom from angina vs. disease free patients, while epicardial revascularization tends to improve symptoms. 

    Original Title: Coronary microvascular disease in patients referred to coronary angiography following coronary computed tomography angiography.

    Reference: Westra J, Rasmussen LD, Karim SR, Jensen RV, Ejlersen JA, Gormsen LC, Bøttcher M, Eftekhari A, Winther S, Christiansen EH. Coronary microvascular disease in patients referred to coronary angiography following coronary computed tomography angiography. EuroIntervention. 2025 Sep 1;21(17):e1005-e1014. doi: 10.4244/EIJ-D-24-01155. PMID: 40887988; PMCID: PMC12378605.


    Subscribe to our weekly newsletter

    Get the latest scientific articles on interventional cardiology

    Dr. Omar Tupayachi
    Dr. Omar Tupayachi
    Member of the Editorial Board of solaci.org

    More articles by this author

    EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

    The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

    EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

    In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

    EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

    This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

    EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

    This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Related Articles

    SOLACI Sessionsspot_img
    Jornadas Guatemala 2026

    Recent Articles

    T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

    Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

    Is left atrial appendage closure safe in patients with reduced ejection fraction?

    Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

    Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

    Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...